Precision Medicine Action for Cancer (PMAC) Announces Key New Liquid Biopsy Findings at the 2025 San Antonio Breast Cancer Symposium
- carolinareduzzi
- 4 days ago
- 2 min read
New York, NY – December 9, 2025 – Precision Medicine Action for Cancer (PMAC), a newly formed non-profit organization dedicated to advancing precision medicine through liquid biopsy, today announced six abstract presentations at the 2025 San Antonio Breast Cancer Symposium.
“Leveraging contributions from over 10 participating institutions, PMAC has established a robust resource: a clinically and molecularly annotated database featuring data from 3,000+ patients with breast cancer who underwent liquid biopsy testing. This database serves as a foundational tool for generating real-world evidence (RWE), specifically investigating the utility of liquid biopsy in enhancing personalized treatment strategies and ultimately improving patient outcomes.” said Massimo Cristofanilli, co-Founder and CEO. “We are eager to showcase crucial research at SABCS 2025 and look forward to continuing momentum for patients into next year and beyond.”
The abstracts represent a significant step forward in understanding and personalizing treatment for both early-stage and metastatic breast cancer. Key highlights from the scientific program include:
Presentation | Title | Presenter | Time/Location |
December 10, 2025 | |||
PS2-07-04 | Time-to-progression patterns during first and second-line endocrine therapy across clinical features and liquid biopsy-defined mutational profiles in HR+/HER2- metastatic breast cancer | Lorenzo Gerratana | 5:00 PM – 6:30 PM | Exhibit Hall |
PS2-09-18 | Real-time liquid biopsy assessment in early-stage breast cancer: methylation-based ctDNA analysis and CTCs detection as potential predictors of response to neoadjuvant therapy | Caterina Gianni | 5:00 PM – 6:30 PM | Exhibit Hall |
PS2-10-11 | Evaluating the impact of neighborhood deprivation on CDK4/6 inhibitor use, outcomes, and circulating tumor DNA (ctDNA) alterations in patients with metastatic breast cancer | Emily Podany | 5:00 PM – 6:30 PM | Exhibit Hall |
December 11, 2025 | |||
PD5-05 | Impact of circulating tumor DNA (ctDNA) surveillance on quality of life (QoL) for patients with early-stage breast cancer (EBC): prospective I-SURV study | Cheng Cheng | 7:00 AM–8:30 AM | Hemisfair 3 |
PS4-02-11 | Molecular and prognostic profiling of HR+/HER2+ Metastatic Breast Cancer (MBC): insights from circulating tumor DNA (ctDNA)-based genomic analysis | Lorenzo Foffano | 5:00 PM – 6:30 PM | Exhibit Hall |
PS4-03-26 | Cell-free DNA BRCA copy number loss and/or deletions in patients with metastatic breast cancer: incidence and association with clinical and genomic features | Neelima Vidula | 5:00 PM – 6:30 PM | Exhibit Hall |
PMAC invites attendees to connect at SABCS 2025 to share insights and discuss collaborative opportunities for advancing breast cancer research and patient outcomes.
“SABCS 2025 will be a great opportunity to connect with global investigators, community oncologists, patient advocates and industry representatives, to foster new collaboration and research opportunities” added Aditya Bardia, co-Founder.
About Precision Medicine Action for Cancer (PMAC)
Precision Medicine Action for Cancer (PMAC) was created in 2017 and established as a non-profit in April 2025 with the goal of fostering multi-institutional collaboration to consolidate liquid biopsy and precision medicine data from patients with breast cancer and other solid tumors. PMAC’s mission is to conduct innovative, high-impact research in precision medicine with the goal to improve the prognosis and care of patients with breast cancer and other solid tumors while fostering education for the next generation of investigators and the broader community. PMAC is founded by two leading physicians in breast cancer, Massimo Cristofanilli, MD, FACP and Aditya Bardia, MD, MPH, FASCO, PMAC.
CONTACT:
Carolina Reduzzi
###
